Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Scribe Therapeutics has initiated a Phase 1 clinical trial of STX-1150, an epigenetic therapy that silences PCSK9 expression in the liver to reduce LDL cholesterol without modifying DNA sequence. Preclinical data demonstrated sustained LDL reductions exceeding 50 percent for approximately 18 months following a single dose, positioning epigenetic regulation as a distinct mechanism from genetic modification for cholesterol management.
Alzinova's ALZ-101 vaccine candidate advanced to Phase 2 following Phase 1b safety data showing no amyloid-related imaging abnormalities, sustained antibody response in cerebrospinal fluid, and exploratory signals in tau and neuroinflammatory biomarkers. This represents progress toward an immunotherapeutic approach to Alzheimer's pathology with a favorable safety profile in early human testing.
MBX Biosciences is advancing precision peptide therapies targeting endocrine and metabolic dysfunction, with candidates in development for hypoparathyroidism and obesity. The company's proprietary platform represents a shift toward mechanism-specific intervention in metabolic disorders rather than broad-spectrum pharmacology.
Multiple biotechs are advancing gene therapies and exon-skipping treatments for Duchenne and myotonic dystrophy toward regulatory approval, with several products expected to file or launch between 2026 and 2027. These developments represent a significant expansion in treatment options for previously intractable muscle-wasting diseases, directly addressing a major source of morbidity and mortality in affected populations.
Cuffless ring-type blood pressure monitors have been incorporated into Korean hypertension guidelines as a Class IIb recommendation for out-of-office monitoring. The CART BP pro device demonstrated accuracy comparable to standard 24-hour ambulatory blood pressure monitoring, offering continuous measurement without the sleep disruption associated with traditional cuff-based approaches.
Daewoong Pharmaceutical acquired Turn Biotechnologies' ERA platform, a partial cellular reprogramming technology that uses mRNA to restore cellular function while preserving cellular identity. This strategic acquisition signals the shift of cellular rejuvenation from laboratory investigation toward pharmaceutical infrastructure and clinical application.
Longevity clinics are transitioning from wellness marketing to accountable preventive healthcare, with industry leaders emphasizing diagnostic rigor, longitudinal data, and continuity of care as prerequisites for clinical credibility. This shift reflects broader healthcare pressure to demonstrate measurable outcomes rather than rely on early-adopter enthusiasm.
Retro Biosciences has secured $1.8 billion in funding while advancing its first human trial of an oral drug designed to restore cellular autophagy and reduce protein accumulation associated with Alzheimer's disease. Early Phase 1 data shows safety tolerability, marking a transition in the longevity sector from animal models toward validated human therapeutics targeting cellular maintenance pathways implicated across multiple age-related diseases.
Lucis, a Paris-based preventive health platform, has raised $20 million to scale longitudinal biomarker tracking across Europe, positioning continuous physiological monitoring as an alternative to reactive healthcare models. The company's 80% retest rate and demonstration that 75% of users improved key biomarkers through lifestyle modifications suggest that sustained engagement with personalized biomarker data can shift behavior before chronic disease develops.
Eli Lilly's retatrutide achieved 28.3% average weight loss over 80 weeks in late-stage trials, with 45% of patients reaching 30% weight loss—a threshold historically reserved for bariatric surgery. This represents a substantial advance in pharmacological obesity treatment and positions metabolic intervention as upstream disease prevention in the aging process.
Tau protein, best known for its pathological role in Alzheimer's disease, is essential for encoding long-term memories in healthy brains. A Flinders University study reveals that tau phosphorylation at threonine-205 during the learning window enables memory consolidation by organizing sparse, precise neural ensembles—opening therapeutic pathways distinct from current tau-reduction strategies.
Women over 80 who maintained positive attitudes toward physical activity throughout their lives showed superior functional fitness and sustained higher activity levels compared to peers. Lifelong psychological orientation toward movement—independent of current exercise volume—emerges as a predictor of late-life physical capacity and independence.